Voies biliaires

  • Accueil
  • Voies biliaires
  • MK-9999-02A

TITRE (EN) A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers
PROTOCOLE ID MK-9999-02A
CLINICAL TRIAL.gov ID NCT06428409
TYPE(S) DE CANCER Voies biliaires
PHASE Phase I-II
TYPE D'ÉTUDE Clinique
INSTITUTION CENTRE UNIVERSITAIRE DE SANTE MCGILL
1001 boul. Décarie
VILLE Montréal
INVESTIGATEUR(RICE) PRINCIPAL(E) Victoria Mandilaras
COORDONATEUR(RICE) Rodrigo Skowronski
rodrigo.skowronski@muhc.mcgill.ca
514-934-1934 poste 36275
STATUT  Actif en recrutement
CRITÈRES D'ÉLIGIBILITÉ (EN)

The main inclusion criteria include but are not limited to the following:

  • Has one of the following cancers:

    • Unresectable or metastatic colorectal cancer
    • Advanced or metastatic pancreatic ductal adenocarcinoma (PDAC)
    • Advanced and/or unresectable biliary tract cancer (BTC)
  • Has received prior therapy for the cancer
  • Has recovered from any side effects due to previous cancer treatment
CRITÈRES D'EXCLUSION (EN)

The main exclusion criteria include but are not limited to the following:

  • History of severe eye disease
  • Received prior systemic anticancer therapy including investigational agents within 4 weeks before starting study intervention
  • History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease